TCT 2017 | Resultados finales del dispositivo Watchman

TCT 2017 | PREVAIL: Final Outcomes of the Watchman Device

TCT 2017 | PREVAIL: Final Outcomes of the Watchman Device

Courtesy of SBHCI. The final 5-year outcomes of the PROTECT AF and PREVAIL studies (which assessed the left atrial appendage closure device Watchman) continues to show similar stroke prevention rate to that of warfarin, though with a clear reduction in bleeding. The meta-analysis showed a significant reduction in hemorrhagic stroke (0.17% vs 0.87%), non-procedure related

TCT 2017 | Estudio TRI-REPAIR y estudio FORMA: nuevos dispositivos para la “válvula olvidada”

TCT 2017 | The TRI-REPAIR and the FORMA Trials: New Devices for the “Forgotten Valve”

Courtesy of SBHCI. Two new transcatheter treatments for severe or massive functional tricuspid regurgitation have showed good results at 30 days, according to their feasibility studies. The long-forgotten tricuspid valve has been gaining more attention with research linking tricuspid regurgitation to an increase in mortality.   Early studies used devices originally designed for the mitral or

TCT 2017 | INTREPID: reemplazo mitral con prótesis autoexpandible

TCT 2017 | INTREPID: Mitral Replacement with a Self-Expanding Device

Courtesy of the SBHCI. Intrepid is a 43-, 46-, and 50-mm nitinol self-expanding valve with bovine pericardial leaflets that is placed using a transapical delivery system with a 35-Fr access. This pilot study enrolled 50 patients with severe mitral regurgitation who were symptomatic and at a high surgical risk, or in whom surgery was contraindicated. Read

TCT 2017 | MAVERIC: resultados a 6 meses del reemplazo mitral por catéter

TCT 2017 | MAVERIC: Results 6 Months After Transcatheter Mitral Valve Replacement

 Courtesy of the SBHCI. This seems to be the year for transcatheter mitral valve devices, and the ARTO system tested in this study looks promising for the treatment of patients with severe mitral regurgitation who are symptomatic due to heart failure and ejection fraction <40%. The study enrolled 50 patients who underwent clinical and ecocardiographic follow-up